Boule Diagnostics

At the Annual General Meeting 2024 (the "AGM") it was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated balance sheet. The AGM resolved to approve that the company's accumulated profit shall be carried forward and that no dividend would be paid for the financial year 2023.

The AGM resolved to to grant the directors and the CEO discharge from liability for the financial year 2023.

The AGM resolved to approve the Nomination Committee's proposal that six directors shall be appointed to the Board of Directors.

The AGM resolved that the chairman shall be paid SEK 500,000 (unchanged) and that all other directors shall be paid SEK 250,000 (unchanged). It was resolved that a total of SEK 120,000 (unchanged) shall be paid to the Remuneration Committee, to be divided within the committee, and also an amount of SEK 50,000 that the Board of Directors can use for special purposes. The total fee to the Board of Directors therefore amounts to a total of SEK 1,920,000.

It was also resolved that the fee to the auditor, in accordance with last year, shall be paid as per specified invoice, approved by the Board of Directors.

The AGM resolved to re-elect the directors Karin Dahllöf, Thomas Eklund, Emil Hjalmarsson, Torben Jørgensen and Yvonne Mårtensson and to elect the new director Rikke Rytter, until the next annual general meeting. The AGM resolved to re-elect Torben Jørgensen as Chairman of the Board of Directors until the next annual general meeting.

It was resolved to re-elect the audit company Öhrlings PriceWaterhouseCoopers AB as the company's auditor, with Lars Kylberg as auditor in charge, until the annual general meeting 2025.

The AGM resolved to approve the proposed principles for appointing members to the Nomination Committee and the instruction for the Nomination Committee.

The AGM resolved to approve the Board of Directors' proposal of guidelines for remuneration to executive management.

The AGM resolved to approve the Board of Directors' presented remuneration report 2023.

The AGM resolved to approve the Board of Directors' proposal regarding authorization for the Board of Directors to resolve on new issue of shares, warrants and/or convertibles.  

The AGM resolved to approve the Board of Directors' proposal regarding authorization for the Board of Directors to resolve on transfer and/or acquisition of own shares.

Complete information regarding the AGM and the separate resolutions can be found on Boule's website, www.boule.com.

For further information, please contact:

Torben Nielsen, CEO and Group President, Boule Diagnostics AB, torben.nielsen@boule.com

Holger Lembrér, CFO, Boule Diagnostics AB, holger.lembrer@boule.com, tfn. +46 (0)72-230 77 10

About Boule Diagnostics AB (publ)

Boule Diagnostics AB (publ) is a global diagnostics company specializing in near-patient, decentralized blood diagnostics and one of the few companies in the global diagnostics market that conducts its own development, manufacturing and marketing of instruments and consumables for blood diagnostics. The Company primarily serves hospitals, clinics, laboratories and other diagnostics companies to which it offers complete systems for blood diagnostics (hematology) in both the human and veterinary areas. Boule has strong positions in important emerging markets such as in Asia and in recent years has improved its position in the fast-growing veterinary market. Operations are conducted through operating subsidiaries in Sweden, the United States, Mexico and Russia. The Group reported net sales of SEK 571 million in 2023 and has more than 200 employees. Sales are conducted globally, predominantly through the company's 200 or so distributors in over 100 countries, supported by Boule's own local sales and service personnel. Boule has been listed on Nasdaq Stockholm since 2011. http://www.boule.com

The information was submitted for publication, through the agency of the contact person set out above, at 18:15 CEST on May 8, 2024.